Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 10;7(12):109.
doi: 10.3390/medsci7120109.

Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management

Travis P Green  1 , Jose Saavedra-Belaunde  1   2 , Run Wang  1   2
Affiliations
Review

Ejaculatory and Orgasmic Dysfunction Following Prostate Cancer Therapy: Clinical Management

Travis P Green et al. Med Sci (Basel). .

Abstract

The majority of sexual health research has focused on erectile dysfunction following prostate cancer treatment. Ejaculatory and orgasmic dysfunction are significant side effects following the treatment of prostate cancer. Orgasmic dysfunction covers a range of issues including premature ejaculation, anorgasmia, dysorgasmia, and climacturia. This review provides an overview of prevalence and management options to deal with orgasmic dysfunction. A Medline Pubmed search was used to identify articles relating to these problems. We found that orgasmic dysfunction has a very large impact on patients' lives following prostate cancer treatment and there are ways for physicians to treat it. Management of patients' sexual health should be focused not only on erectile dysfunction, but on orgasmic dysfunction as well in order to ensure a healthy sexual life for patients and their partners.

Keywords: anejaculation; climacturia; dysorgasmia; ejaculatory dysfunction; orgasm; painful ejaculation; premature ejaculation; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Howlader N., Noone A.M., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., et al. SEER Cancer Statistics Review, 1975–2014. National Cancer Institute; Bethesda, MD, USA: 2018. [(accessed on 1 June 2019)]. Available online: https://seer.cancer.gov/statfacts/html/prost.html.
    1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2007;57:43–66. doi: 10.3322/canjclin.57.1.43. - DOI - PubMed
    1. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J. Natl. Cancer Inst. 2009;101:1325–1329. doi: 10.1093/jnci/djp278. - DOI - PMC - PubMed
    1. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., Carroll P.R. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J. Clin. Oncol. 2004;22:2141–2149. doi: 10.1200/JCO.2004.10.062. - DOI - PMC - PubMed
    1. Abdollah F., Sun M., Schmitges J., Thuret R., Bianchi M., Shariat S.F., Briganti A., Jeldres C., Perrotte P., Montorsi F., et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: Estimations of the number needed to treat according to tumor and patient characteristics. J. Urol. 2012;188:73–83. doi: 10.1016/j.juro.2012.03.005. - DOI - PubMed

LinkOut - more resources